Ardelyx(ARDX) - 2025 Q4 - Annual Results

Financial Performance - Unaudited U.S. net product sales revenue of IBSRELA (tenapanor) was approximately $87 million for Q4 2025 and approximately $274 million for the full year 2025[9] - Unaudited U.S. net product sales revenue of XPHOZAH (tenapanor) was approximately $28 million for Q4 2025 and approximately $104 million for the full year 2025[9] Cash Position - As of December 31, 2025, Ardelyx, Inc. reported cash, cash equivalents, and short-term investments of approximately $265 million, unaudited[4]